Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes

Infection and Immunity

Volumn 83, Issue 2, 2015, Pages 792-801

  Herrera, Bruno S ^a   Hasturk, Hatice ^a   Kantarci, Alpdogan ^a   Freire, Marcelo O ^a   Nguyen, Olivia ^a   Kansal, Shevali ^a   van Dyke, Thomas E ^a  

^a FORSYTH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID DERIVATIVE; FLUORESCEIN ISOTHIOCYANATE; FLUOROCHROME; ICOSAPENTAENOIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; RESOLVIN E1; SERINE; THREONINE; UNCLASSIFIED DRUG; 5S,12R,18R-TRIHYDROXY-6Z,8E,10E,14Z,16E-EICOSAPENTAENOIC ACID; GLUCOSE BLOOD LEVEL;

AIR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; CELL ISOLATION; CONTROLLED STUDY; DORSAL AIR POUCH MODEL; FLOW CYTOMETRY; FLUOROCHROME STAINING; GENE OVEREXPRESSION; GENETIC ENGINEERING; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; INFLAMMATION; MALE; MOUSE; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHAGOCYTOSIS; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE; WESTERN BLOTTING; WILD TYPE; ANALOGS AND DERIVATIVES; ANIMAL; BACTEROIDACEAE INFECTION; DIABETES MELLITUS; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; GLYCOSYLATION; IMMUNOLOGY; LIPID METABOLISM; METABOLISM; MOUSE MUTANT; OBESITY; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALS; BACTEROIDACEAE INFECTIONS; BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; EICOSAPENTAENOIC ACID; FLOW CYTOMETRY; GLYCOSYLATION; INFLAMMATION; LIPID METABOLISM; MALE; MICE; MICE, OBESE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEUTROPHILS; OBESITY; PHAGOCYTOSIS; PHOSPHORYLATION; PORPHYROMONAS GINGIVALIS;

EID: 84921324693     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.02444-14     Document Type: Article

References (60)

1. Eke PI, Dye BA, Wei L, Thornton-Evans GO, Genco RJ, Beck J, Douglass G, Page R. 2012. Prevalence of periodontitis in adults in the United States: 2009 and 2010. J Dent Res 91:914-920. http://dx.doi.org/10.1177/0022034512457373.
2. Libby P. 2002. Atherosclerosis: the new view. SciAm 286:46-55. http://dx.doi.org/10.1038/scientificamerican0502-46.
3. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. 2005. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111:1448-1454. http://dx.doi.org/10.1161/01.CIR.0000158483.13093.9D.
4. Graves DT, Kayal RA. 2008. Diabetic complications and dysregulated innate immunity. Front Biosci 13:1227-1239. http://dx.doi.org/10.2741/2757.
5. Pacios S, Kang J, Galicia J, Gluck K, Patel H, Ovaydi-Mandel A, Petrov S, Alawi F, Graves DT. 2012. Diabetes aggravates periodontitis by limiting repair through enhanced inflammation. FASEB J 26:1423-1430. http://dx.doi.org/10.1096/fj.11-196279.
6. Champion OL, Valdez Y, Thorson L, Guttman JA, Menendez A, Gaynor EC, Finlay BB. 2008. A murine intraperitoneal infection model reveals that host resistance to Campylobacter jejuni is Nramp1 dependent. Microbes Infect 10:922-927. http://dx.doi.org/10.1016/j.micinf.2008.05.001.
7. Hasturk H, Kantarci A, Goguet-Surmenian E, Blackwood A, Andry C, Serhan CN, Van Dyke TE. 2007. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol 179:7021-7029. http://dx.doi.org/10.4049/jimmunol.179.10.7021.
8. Braun J, Wei B. 2007. Body traffic: ecology, genetics, and immunity in inflammatory bowel disease. Annu Rev Pathol 2:401-429. http://dx.doi.org/10.1146/annurev.pathol.1.110304.100128.
9. Andoh A, Benno Y, Kanauchi O, Fujiyama Y. 2009. Recent advances in molecular approaches to gut microbiota in inflammatory bowel disease. Curr Pharm Des 15:2066-2073. http://dx.doi.org/10.2174/138161209788489186.
10. Shih DQ, Targan SR, McGovern D. 2008. Recent advances in IBD pathogenesis: genetics and immunobiology. Curr Gastroenterol Rep 10: 568-575. http://dx.doi.org/10.1007/s11894-008-0104-x.
11. Iacopino AM. 2001. Periodontitis and diabetes interrelationships: role of inflammation. Ann Periodontol 6:125-137. http://dx.doi.org/10.1902/annals.2001.6.1.125.
12. Gilroy DW, Lawrence T, Perretti M, Rossi AG. 2004. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 3:401-416. http://dx.doi.org/10.1038/nrd1383.
13. Serhan CN. 2010. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol 177:1576-1591. http://dx.doi.org/10.2353/ajpath.2010.100322.
14. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. 2000. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192:1197-1204. http://dx.doi.org/10.1084/jem.192.8.1197.
15. Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, Chiang N, Petasis NA, Levy BD, Serhan CN, Van Dyke TE. 2006. RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. FASEB J 20:401-403. http://dx.doi.org/10.1096/fj.05-4724fje.
16. Khanna S, Biswas S, Shang Y, Collard E, Azad A, Kauh C, Bhasker V, Gordillo GM, Sen CK, Roy S. 2010. Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PLoS One 5:e9539. http://dx.doi.org/10.1371/journal.pone.0009539.
17. Spite M, Norling LV, Summers L, Yang R, Cooper D, Petasis NA, Flower RJ, Perretti M, Serhan CN. 2009. Resolvin D2 is a potent regu-lator of leukocytes and controls microbial sepsis. Nature 461:1287-1291. http://dx.doi.org/10.1038/nature08541.
18. Omori K, Ohira T, Uchida Y, Ayilavarapu S, Batista EL, Jr, Yagi M, Iwata T, Liu H, Hasturk H, Kantarci A, Van Dyke TE. 2008. Priming of neutrophil oxidative burst in diabetes requires preassembly of the NADPH oxidase. J Leukoc Biol 84:292-301. http://dx.doi.org/10.1189/jlb.1207832.
19. Wierusz-Wysocka B, Wysocki H, Siekierka H, Wykretowicz A, Szczepanik A, Klimas R. 1987. Evidence of polymorphonuclear neutrophils (PMN) activation in patients with insulin-dependent diabetes mellitus. J Leukoc Biol 42:519-523.
20. Gyurko R, Siqueira CC, Caldon N, Gao L, Kantarci A, Van Dyke TE. 2006. Chronic hyperglycemia predisposes to exaggerated inflammatory response and leukocyte dysfunction in Akita mice. J Immunol 177:7250-7256. http://dx.doi.org/10.4049/jimmunol.177.10.7250.
21. Coleman DL. 1982. Diabetes-obesity syndromes in mice. Diabetes 31(Suppl 1 Pt 2):1-6.
22. Coleman DL, Hummel KP. 1974. Hyperinsulinemia in pre-weaning diabetes (db) mice. Diabetologia 10(Suppl):607-610. http://dx.doi.org/10.1007/BF01221993.
23. Um YJ, Jung UW, Kim CS, Bak EJ, Cha JH, Yoo YJ, Choi SH. 2010. The influence of diabetes mellitus on periodontal tissues: a pilot study. J Periodontal Implant Sci 40:49-55. http://dx.doi.org/10.5051/jpis.2010.40.2.49.
24. Hisada T, Ishizuka T, Aoki H, Mori M. 2009. Resolvin E1 as a novel agent for the treatment of asthma. Expert Opin Ther Targets 13:513-522. http://dx.doi.org/10.1517/14728220902865622.
25. Tian H, Lu Y, Sherwood AM, Hongqian D, Hong S. 2009. Resolvins E1 and D1 in choroid-retinal endothelial cells and leukocytes: biosynthesis and mechanisms of anti-inflammatory actions. Invest Ophthalmol Vis Sci 50:3613-3620. http://dx.doi.org/10.1167/iovs.08-3146.
26. Fredman G, Oh SF, Ayilavarapu S, Hasturk H, Serhan CN, Van Dyke TE. 2011. Impaired phagocytosis in localized aggressive periodontitis: rescue by resolvin E1. PLoS One 6:e24422. http://dx.doi.org/10.1371/journal.pone.0024422.
27. Van Dyke TE. 2008. The management of inflammation in periodontal disease. J Periodontol 79:1601-1608. http://dx.doi.org/10.1902/jop.2008.080173.
28. Nathan C, Ding A. 2010. Nonresolving inflammation. Cell 140:871-882. http://dx.doi.org/10.1016/j.cell.2010.02.029.
29. Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, Yang R, Petasis NA, Serhan CN. 2010. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A 107: 1660-1665. http://dx.doi.org/10.1073/pnas.0907342107.
30. Merched AJ, Ko K, Gotlinger KH, Serhan CN, Chan L. 2008. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J 22:3595-3606. http://dx.doi.org/10.1096/fj.08-112201.
31. Freire MO, Van Dyke TE. 2013. Natural resolution of inflammation. Periodontol 2000 63:149-164. http://dx.doi.org/10.1111/prd.12034.
32. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN. 2005. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 201:713-722. http://dx.doi.org/10.1084/jem.20042031.
33. Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN. 2007. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 178:3912-3917. http://dx.doi.org/10.4049/jimmunol.178.6.3912.
34. Serhan CN, Chiang N, Van Dyke TE. 2008. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8:349-361. http://dx.doi.org/10.1038/nri2294.
35. Oh SF, Pillai PS, Recchiuti A, Yang R, Serhan CN. 2011. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J Clin Invest 121:569-581. http://dx.doi.org/10.1172/JCI42545.
36. Gao L, Faibish D, Fredman G, Herrera BS, Chiang N, Serhan CN, Van Dyke TE, Gyurko R. 2013. Resolvin E1 and chemokine-like receptor 1 mediate bone preservation. J Immunol 190:689-694. http://dx.doi.org/10.4049/jimmunol.1103688.
37. Genco CA, Cutler CW, Kapczynski D, Maloney K, Arnold RR. 1991. A novel mouse model to study the virulence of and host response to Porphyromonas (Bacteroides) gingivalis. Infect Immun 59:1255-1263.
38. Genco CA, Schifferle RE, Njoroge T, Forng RY, Cutler CW. 1995. Resistance of a Tn4351-generated polysaccharide mutant of Porphyromonas gingivalis to polymorphonuclear leukocyte killing. Infect Immun 63: 393-401.
39. Polak D, Shapira L, Weiss EI, Houri-Haddad Y. 2012. The role of coaggregation between Porphyromonas gingivalis and Fusobacterium nucleatum on the host response to mixed infection. J Clin Periodontol 39:617-625. http://dx.doi.org/10.1111/j.1600-051X.2012.01889.x.
40. Amano A, Ishimoto T, Tamagawa H, Shizukuishi S. 1992. Role of superoxide dismutase in resistance of Porphyromonas gingivalis to killing by polymorphonuclear leukocytes. Infect Immun 60:712-714.
41. Kobayashi T, Yamamoto K, Sugita N, van Spriel AB, Kaneko S, van de Winkel JG, Yoshie H. 2001. Effective in vitro clearance of Porphyromonas gingivalis by Fc alpha receptor I (CD89) on gingival crevicular neutrophils. Infect Immun 69:2935-2942. http://dx.doi.org/10.1128/IAI.69.5.2935-2942.2001.
42. Sin YM, Sedgwick AD, Chea EP, Willoughby DA. 1986. Mast cells in newly formed lining tissue during acute inflammation: a six day air pouch model in the mouse. Ann Rheum Dis 45:873-877. http://dx.doi.org/10.1136/ard.45.10.873.
43. Hachicha M, Pouliot M, Petasis NA, Serhan CN. 1999. Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alphainitiated neutrophil responses and trafficking: regulators of a cytokinechemokine axis. J ExpMed 189:1923-1930. http://dx.doi.org/10.1084/jem.189.12.1923.
44. Apovian CM, Bigornia S, Mott M, Meyers MR, Ulloor J, Gagua M, McDonnell M, Hess D, Joseph L, Gokce N. 2008. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol 28:1654-1659. http://dx.doi.org/10.1161/ATVBAHA.108.170316.
45. Liu MJ, Bao S, Bolin ER, Burris DL, Xu X, Sun Q, Killilea DW, Shen Q, Ziouzenkova O, Belury MA, Failla ML, Knoell DL. 2013. Zinc deficiency augments leptin production and exacerbates macrophage infiltration into adipose tissue in mice fed a high-fat diet. J Nutr 143:1036-1045. http://dx.doi.org/10.3945/jn.113.175158.
46. McDonnell ME, Ganley-Leal LM, Mehta A, Bigornia SJ, Mott M, Rehman Q, Farb MG, Hess DT, Joseph L, Gokce N, Apovian CM. 2012. B lymphocytes in human subcutaneous adipose crown-like structures. Obesity 20:1372-1378. http://dx.doi.org/10.1038/oby.2012.54.
47. Taylor GW, Burt BA, Becker MP, Genco RJ, Shlossman M, Knowler WC, Pettitt DJ. 1996. Severe periodontitis and risk for poor glycemic control in patients with non-insulin-dependent diabetes mellitus. J Periodontol 67:1085-1093. http://dx.doi.org/10.1902/jop.1996.67.10s.1085.
48. Schwab JM, Chiang N, Arita M, Serhan CN. 2007. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447: 869-874. http://dx.doi.org/10.1038/nature05877.
49. Ishida T, Yoshida M, Arita M, Nishitani Y, Nishiumi S, Masuda A, Mizuno S, Takagawa T, Morita Y, Kutsumi H, Inokuchi H, Serhan CN, Blumberg RS, Azuma T. 2010. Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodiuminduced colitis. Inflamm Bowel Dis 16:87-95. http://dx.doi.org/10.1002/ibd.21029.
50. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, Blumberg RS, Serhan CN. 2005. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A 102:7671-7676. http://dx.doi.org/10.1073/pnas.0409271102.
51. González-Périz A, Horrillo R, Ferre N, Gronert K, Dong B, Moran-Salvador E, Titos E, Martinez-Clemente M, Lopez-Parra M, Arroyo V, Clària J. 2009. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 23:1946-1957. http://dx.doi.org/10.1096/fj.08-125674.
52. Hellmann J, Tang Y, Kosuri M, Bhatnagar A, Spite M. 2011. Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J 25:2399-2407. http://dx.doi.org/10.1096/fj.10-178657.
53. Clària J, Dalli J, Yacoubian S, Gao F, Serhan CN. 2012. Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J Immunol 189: 2597-2605. http://dx.doi.org/10.4049/jimmunol.1201272.
54. Ohira T, Arita M, Omori K, Recchiuti A, Van Dyke TE, Serhan CN. 2010. Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem 285:3451-3461. http://dx.doi.org/10.1074/jbc.M109.044131.
55. Herrera BS, Ohira T, Gao L, Omori K, Yang R, Zhu M, Muscara MN, Serhan CN, Van Dyke TE, Gyurko R. 2008. An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption. Br J Pharmacol 155:1214-1223. http://dx.doi.org/10.1038/bjp.2008.367.
56. Cash JL, Bena S, Headland SE, McArthur S, Brancaleone V, Perretti M. 2013. Chemerin15 inhibits neutrophil-mediated vascular inflammation and myocardial ischemia-reperfusion injury through ChemR23. EMBO Rep 14:999-1007. http://dx.doi.org/10.1038/embor.2013.138.
57. Tuttle HA, Davis-Gorman G, Goldman S, Copeland JG, McDonagh PF. 2003. Platelet-neutrophil conjugate formation is increased in diabetic women with cardiovascular disease. Cardiovasc Diabetol 2:12. http://dx.doi.org/10.1186/1475-2840-2-12.
58. Löe H. 1993. Periodontal disease. The sixth complication of diabetes mellitus. Diabetes Care 16:329-334.
59. Engebretson SP, Hyman LG, Michalowicz BS, Schoenfeld ER, Gelato MC, Hou W, Seaquist ER, Reddy MS, Lewis CE, Oates TW, Tripathy D, Katancik JA, Orlander PR, Paquette DW, Hanson NQ, Tsai MY. 2013. The effect of nonsurgical periodontal therapy on hemoglobin A1c levels in persons with type 2 diabetes and chronic periodontitis: a randomized clinical trial. JAMA 310:2523-2532. http://dx.doi.org/10.1001/jama.2013.282431.
60. Chapple IL, Borgnakke WS, Genco RJ. 2014. Hemoglobin A1c levels among patients with diabetes receiving nonsurgical periodontal treatment. JAMA 311:1919-1920. http://dx.doi.org/10.1001/jama.2014.2228.